2011
Targeted Therapy for Malignant Gliomas
Dankwah-Quansah M, Omuro A. Targeted Therapy for Malignant Gliomas. Tumors Of The Central Nervous System 2011, 299-307. DOI: 10.1007/978-94-007-0344-5_31.Peer-Reviewed Original ResearchMalignant gliomasAggressive primary brain tumorFatal disease outcomeSingle-agent trialsSingle-agent treatmentPrimary brain tumorsAkt/mTORDevelopment of combinationsAgent trialsDismal prognosisPatient selectionStandard treatmentTargeted therapyDisease outcomeAnaplastic astrocytomaAnaplastic oligodendrogliomaBrain tumorsTherapy trialsNew treatmentsPathway inhibitionGliomasAgent treatmentTrialsRas/MAPKPromising activity
2008
What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Current Opinion In Neurology 2008, 21: 717-719. PMID: 18989118, DOI: 10.1097/wco.0b013e3283184625.Peer-Reviewed Original ResearchConceptsMalignant gliomasOverall survivalClinical trialsProspective phase II trialPlace of bevacizumabProgression-free survivalPhase II trialNew treatment strategiesHigh response rateTreatment of glioblastomaII trialRecurrent diseaseSalvage treatmentCytotoxic chemotherapyMost patientsConventional radiographic methodsDisease progressionHistorical controlsSurvival resultsRadiographic criteriaTreatment strategiesBevacizumabResponse rateNew treatmentsGliomas